New Independent Study Establishes the Octave MSDA Test as an Objective Measure to Distinguish True MS Relapse from Pseudoexacerbation

MENLO PARK, Calif.--(BUSINESS WIRE)-- #MultipleSclerosis--Octave Bioscience, Inc., a commercial-stage precision neurology company pioneering a new standard for managing multiple sclerosis (MS) and other neurodegenerative diseases such as Parkinson’s disease, today announced publication of an independent, investigator-initiated study in the journal Neurology and Therapy evaluating the Octave® Multiple Sclerosis Disease Activity (MSDA) Test in one of the most consequential judgment calls in MS car